<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761161</url>
  </required_header>
  <id_info>
    <org_study_id>PTF5</org_study_id>
    <nct_id>NCT02761161</nct_id>
  </id_info>
  <brief_title>Treatment of Sleep Disturbances in Trauma-affected Refugees</brief_title>
  <acronym>PTF5</acronym>
  <official_title>Treatment of Sleep Disturbances in Trauma-affected Refugees: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mental Health Services in the Capital Region, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Center for Sleep Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mental Health Services in the Capital Region, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to examine the effects of sleep enhancing treatment in&#xD;
      refugees with PTSD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Sleep disturbances are often referred to as a hallmark of PTSD. In a sample of 734&#xD;
      trauma-affected refugees undergoing psychiatric treatment at Competence Centre for&#xD;
      Transcultural Psychiatry (CTP) in the period 2008-2012 99% reported sleep disturbances and&#xD;
      nightmares.&#xD;
&#xD;
      In trauma-affected populations untreated sleep disturbances can uphold and exacerbate both&#xD;
      sleep-related and non-sleep-related PTSD symptoms. Sleep disturbances may also affect the&#xD;
      efficacy of first-line PTSD treatment and constitute a risk factor for poor outcome of&#xD;
      psychiatric treatment. It has been argued that effective treatment of sleep disturbances may&#xD;
      accelerate recovery in PTSD. There is a lack of randomised clinical trials on this relation&#xD;
      in trauma-affected refugees.&#xD;
&#xD;
      The aim of this study is to examine sleep enhancing treatment in refugees with PTSD.&#xD;
&#xD;
      MATERIALS AND METHOD:&#xD;
&#xD;
      The study will include 230 refugees, diagnosed with PTSD, referred to CTP. Patients who give&#xD;
      informed consent will be randomised to four treatment groups.&#xD;
&#xD;
        1. Treatment as usual (TAU); pharmacological treatment according to algorithm and manual&#xD;
           based Cognitive Behavioural Therapy&#xD;
&#xD;
        2. TAU and add-on treatment with mianserin&#xD;
&#xD;
        3. TAU and add-on treatment with Imagery Rehearsal Therapy (IRT)&#xD;
&#xD;
        4. TAU and add-on treatment with mianserin and IRT&#xD;
&#xD;
      RESULTS:&#xD;
&#xD;
      This study is expected to bring forward new knowledge on both medical and therapeutic&#xD;
      treatment of sleep disturbances in trauma-affected refugees.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep on The Pittsburgh Sleep Quality Index</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nightmares on the Disturbing Dreams and Nightmare Severity Index</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of PTSD on The Harvard Trauma Questionnaire</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression and anxiety on the Hopkins Symptom Check List</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality on the WHO-5</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of functioning on the Sheehan Disability Scale</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep on the REM Sleep Behavior Disorder Screening Questionnaire</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain on the Brief Pain Inventory short form</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of functioning on the Global Assessment of functioning - Symptoms</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of functioning on WHODAS 2.0</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression and anxiety on Hamilton depression and anxiety scales</measure>
    <time_frame>Change from baseline after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep on Actigraph</measure>
    <time_frame>two weeks recording at baseline and two weeks recording after approximately 6-8 months treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Treatment as usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>TAU: medicine according to algorithm, manual-based cognitive therapy, psychoeducation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mianserin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10-30 mg of mianserin af sleep enhancing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imagery Rehearsal Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy focusing on nightmares</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mianserin and Imagery Rehearsal Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Both mianserin and IRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mianserin</intervention_name>
    <description>mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.</description>
    <arm_group_label>Mianserin</arm_group_label>
    <arm_group_label>mianserin and Imagery Rehearsal Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Imagery Rehearsal Therapy</intervention_name>
    <description>IRT is add-on treatment to treatment as usual.</description>
    <arm_group_label>Imagery Rehearsal Therapy</arm_group_label>
    <arm_group_label>mianserin and Imagery Rehearsal Therapy</arm_group_label>
    <other_name>IRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18 years or older)&#xD;
&#xD;
          -  Refugees or persons who have been family reunified with a refugee&#xD;
&#xD;
          -  PTSD pursuant to the International Classification of Diseases ICD-10 research criteria&#xD;
&#xD;
          -  Psychological trauma experienced outside Denmark in the anamnesis. Trauma is&#xD;
             imprisonment or detention with torture (according to the United Nation definition of&#xD;
             torture) or acts of cruel, inhuman and degrading treatment or punishment. Trauma can&#xD;
             also be organised violence, long-term political persecution and harassment, or war and&#xD;
             civil war experiences.&#xD;
&#xD;
          -  Sleep disturbances/ PSQI &gt;8&#xD;
&#xD;
          -  Nightmares/ HTQ score on nightmare item â‰¥ &quot;a little&quot;&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe psychotic disorder (defined as patients with an ICD-10 diagnosis F2x and&#xD;
             F30.1-F31.9). Patients are excluded only if the psychotic-like experiences are&#xD;
             assessed to be part of an independent psychotic disorder and not part of a severe PTSD&#xD;
             and/or depression&#xD;
&#xD;
          -  Current abuse of drugs or alcohol (F1x.24-F1x.26)&#xD;
&#xD;
          -  Known neurodegenerative disorder (Alzheimer's disease (AD), Parkinson's disease (PD),&#xD;
             Levy-Body dementia (LBD))&#xD;
&#xD;
          -  In need of admission to psychiatric hospital&#xD;
&#xD;
          -  Pregnant and breastfeeding women and women of the reproductive age who wish to&#xD;
             conceive during the project period.&#xD;
&#xD;
          -  Allergy towards active ingredients or excipients in mianserin&#xD;
&#xD;
          -  Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hinuga Sandahl, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Competence Centre for Transcultural Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Competence Centre for Transcultural Psychiatry</name>
      <address>
        <city>Copenhagen</city>
        <state>Ballerup</state>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Sleep</keyword>
  <keyword>Refugee</keyword>
  <keyword>IRT</keyword>
  <keyword>Mianserin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 20, 2021</submitted>
    <returned>October 15, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

